EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms

Wallace Klein Schwengber, Jeremiah Sanders, Aubrey Pinteric, Lindsey Armitage, Daniel S Childs, Thorvardur R Halfdanarson, Mrinal Patnaik, Felipe Martinez, Mohamad Bassam Sonbol, Yael Kusne

Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1696-1704

DOI: 10.2967/jnumed.126.272210 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.08.2026. Verfasst von Wallace Klein Schwengber und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic, Phoenix, Arizona. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Clonal Hematopoiesis, Neoplasms, Radiation-Induced. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceutical therapy (RPT) uses radionuclides linked to targeting ligands to bind tumor-associated receptors or antigens and deliver ionizing radiation to malignant cells. Approved agents include [177Lu]Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumors, [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer, and 223Ra-dichloride for bone-predominant metastatic castration-resistant prostate cancer. Accumulating evidence suggests that RPT may impose genotoxic stress on the hematopoietic system, resulting in prolonged cytopenias and, in some patients, therapy-related myeloid neoplasms (tMNs). This review synthesizes evidence regarding hematologic toxicities associated with [177Lu]Lu-based RPT, emphasizing mechanisms of marrow injury, limitations of dose-only frameworks, host susceptibility factors, and emerging strategies for risk stratification, monitoring, and mitigation. We propose an integrated radiogenomic framework in which hematologic toxicity and tMN risk after RPT may arise from interactions among prior genotoxic exposure, heterogeneous red marrow radiation delivery, host genomic susceptibility-including clonal hematopoiesis and germline predisposition-and baseline marrow reserve. As RPT moves into earlier lines of therapy and populations with a longer expected survival, anticipating hematologic consequences will be essential for safe and precise clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsClonal HematopoiesisNeoplasms, Radiation-InducedHumansAnimals

Stichwörter der Autor:innen

clonal hematopoiesisneuroendocrine tumorsprostate cancerradiopharmaceutical therapytherapy-related myeloid neoplasms

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Medicine, Mayo Clinic, Phoenix, Arizona.
  • Department of Radiology, Mayo Clinic, Phoenix, Arizona.
  • Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
  • Department of Oncology, Mayo Clinic, Rochester, Minnesota; and.
  • Department of Hematology, Mayo Clinic, Rochester, Minnesota.
  • Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona; kusne.yael@mayo.edu.

Zitieren

APA

Schwengber, W. K., Sanders, J., Pinteric, A., Armitage, L., Childs, D. S., Halfdanarson, T. R., Patnaik, M., Martinez, F., Sonbol, M. B., & Kusne, Y. (2026). Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms. Journal of Nuclear Medicine, 67(11), 1696-1704. https://doi.org/10.2967/jnumed.126.272210

Vancouver

Schwengber WK, Sanders J, Pinteric A, Armitage L, Childs DS, Halfdanarson TR, et al. Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms. Journal of Nuclear Medicine. 2026;67(11):1696-1704. doi:10.2967/jnumed.126.272210

BibTeX
@article{Schwengber2026,
  author = {Schwengber, Wallace Klein and Sanders, Jeremiah and Pinteric, Aubrey and Armitage, Lindsey and Childs, Daniel S and Halfdanarson, Thorvardur R and Patnaik, Mrinal and Martinez, Felipe and Sonbol, Mohamad Bassam and Kusne, Yael},
  title = {Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {1696--1704},
  doi = {10.2967/jnumed.126.272210}
}
Kostenlos starten →